Did you know that digestive health is emerging as one of the fastest-growing areas in global healthcare? Growing travel activity, changing lifestyles, and increasing awareness of gastrointestinal conditions are driving demand for digestive health solutions worldwide. With millions of people affected by digestive disorders each year, the sector continues to present significant opportunities for innovation, commercial development, and long-term growth.

As this market evolves, companies with differentiated products and expanding commercial reach are well positioned to capitalise on these trends. Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is one such company, growing its presence through increasing commercial sales, portfolio expansion, and a broader international footprint. Its flagship products, Travelan® and ProIBS®, are designed to support digestive health by addressing travellers' diarrhoea and irritable bowel syndrome, while its immune-based technology platform supports a broader gastrointestinal health strategy.

To explore the company's progress and what's next, join us for an exclusive webinar with Steve Lydeamore, Chief Executive Officer of Immuron Limited. Steve will discuss Immuron's commercial performance, expanding product portfolio, global growth strategy, and the key opportunities shaping the company's next phase of development. The session will also provide insights into recent sales momentum, international market expansion, and the outlook for the digestive health sector.

Date: 20 July 2026
Time: 12:30 PM (Sydney Time).

Seats are limited—register now and don't miss this opportunity to hear directly from the CEO.